Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.
Synthorx wants a $100 million IPO, but is the window closing?
In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In…
The FDA granted a de novo clearance to Atlantic Therapeutics’ electrical muscle stimulator for women, for treating stress urinary incontinence.
Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business.
Former Bayer VP Alan Westwood has taken the reins of British antimicrobial biotech Matoke Pharma.
Elliot Ehrich, M.D., who capped an 18-year career at Alkermes in January, has joined Expansion Therapeutics as its chief medical officer.
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Mesoblast shares dive after its stem cell therapy fails to wean heart failure patients off left ventricular assist devices in a phase 2 trial.
The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech.
NextCure will use the series B funds to advance Siglec-15-targeting antibody NC318 and another asset through early-phase clinical development.